Cancer dependency to PI3K activation (including breast and pancreatic cancers) provided the rationale for development of inhibitors targeting the PI3K/AKT pathway (reviewed in Ellis and Ma [2019]) for their treatment. This evidence concerns the gene PIK3CD and familial pancreatic carcinoma.